Discover how a simple shift toward spermidine-rich foods can activate your body’s natural cellular renewal system, protecting ...
Imneskibart will now enter late-stage trials after the drug offered durable tumour shrinkage in NSCLC, melanoma and other ...
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the ...
As of Friday, November 07, CytomX Therapeutics, Inc.’s CTMX share price has dipped by 18.38%, which has investors questioning ...
Validated Assay Can Test for Interferon Activity in Pediatric Inflammatory Diseases Using Biomarkers
The assay is fast and simple and has already shown clinical utility, although its interpretation may be limited by reference ...
As of September 30, 2025, Corvus had cash, cash equivalents and marketable securities of $65.7 million as compared to $52.0 million as of December 31, 2024. Consistent with last quarter, Corvus ...
To make the therapy safer and more adaptable, UChicago researchers developed a new “split” system called GA1CAR. This uses ...
Newly released preclinical data to be presented in a poster on November 8, 2025SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- ...
Recently, a team led by Academician Hongjie Zhang, Researcher Shuyan Song, Associate Researcher Pengpeng Lei, and Dr. Ran An at the Changchun Institute of Applied Chemistry, Chinese Academy of ...
Recent research suggests that building muscle may stave off erectile dysfunction. We ask experts to break it down.
Q3 2025 Earnings Call Transcript October 28, 2025 Operator: Thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback